Sentence: This study aimed to investigate the therapeutic responses of lung cancer mice models with adenocarcinoma HCC827 ( gefitinib sensitive ) and HCC827R ( gefitinib resistant ) to the epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib alone and in combination with the anti-angiogenesis agent bevacizumab using dynamic contrast enhanced ( DCE ) and diffusion-weighted MRI .
Drug combination annotation:
[{'class': 'POS', 'spans': ['gefitinib', 'erlotinib'], 'is_context_needed': True}, {'class': 'POS', 'spans': [0, 2, 3], 'is_context_needed': True}]